(58 days)
LIFEPAK 12 Defibrillator/Monitor
Not Found
No
The document does not mention AI, ML, or related terms, and the device description focuses on standard defibrillator/monitor functionalities.
Yes
The device is described as a defibrillator/monitor that provides therapies such as defibrillation (for ventricular tachycardia and ventricular fibrillation), synchronized cardioversion (for atrial fibrillation), and noninvasive pacing (for symptomatic bradycardia and asystole). These functions directly treat medical conditions, defining it as a therapeutic device.
Yes
The device explicitly mentions "SpO2 Monitoring" as being indicated for assessing a patient's oxygen saturation level, which is a diagnostic function.
No
The device description explicitly states it is a "full-featured manual defibrillator," which is a hardware device. The summary also mentions waveform analysis and animal testing, which are typical for hardware performance evaluation.
Based on the provided text, the Heartstream XL Defibrillator/Monitor is not an IVD (In Vitro Diagnostic) device.
Here's why:
- IVD devices are used to examine specimens derived from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
- The description of the Heartstream XL Defibrillator/Monitor clearly states its function is for external defibrillation, intra-thoracic defibrillation, delivery of synchronized shocks, and noninvasive external pacing. These are all procedures performed directly on the patient's body, not on specimens taken from the body.
- The intended use and device description focus on treating cardiac conditions through electrical therapy and monitoring physiological parameters (like SpO2), not on analyzing biological samples.
Therefore, the Heartstream XL Defibrillator/Monitor falls under the category of a therapeutic and monitoring medical device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The Heartstream XL Defibrillator/Monitor is for use for the termination of ventricular tachycardia and ventricular fibrillation.
The device is for use by qualified medical personnel trained in the operation of the device and qualified by training in basic life support, advanced cardiac support, or defibrillation. It must be used by or on the order of a physician.
The SMART Biphasic waveform utilized in the Heartstream XL Defibrillator/Monitor has previously undergone clinical testing in adults. These trials support the waveform's effectiveness for defibrillation of ventricular tachyarrhythmias at 150J.
AED Therapy: To be used in the presence of a suspected cardiac arrest on patients of at least 8 years of age that are unresponsive, not breathing and pulseless.
Manual Defibrillation: Asynchronous defibrillation is the initial treatment for ventricular fibrillation and ventricular tachycardia in patients that are pulseless and unresponsive. The SMART Biphasic waveform utilized in the Heartstream XL Defibrillator/Monitor incorporates some user selectable lower energy levels that were not used in the clinical trials.
Synchronized defibrillation is indicated for termination of atrial fibrillation. The SMART Biphasic waveform utilized in the Heartstream XL has undergone clinical testing demonstrating its safety and effectiveness for cardioversion of atrial fibrillation.
There are currently no clinical studies related to the use of SMART Biphasic waveform in pediatric applications.
Pacing: Noninvasive pacing is one method of treating patients with symptomatic bradycardia. It can also be helpful in patients with asystole, if performed early.
SpO2 Monitoring: SpO2 monitoring is indicated for use when it is beneficial to assess a patient's oxygen saturation level.
Product codes
MKJ, LDD
Device Description
The Heartstream XL Defibrillator/Monitor is a full-featured manual defibrillator, designed for use by clinicians trained in Advanced Cardiac Life Support (ACLS) procedures. Manual operation allows users to select biphasic waveform energy levels for external defibrillation, intra-thoracic defibrillation, delivery of synchronized shocks, and noninvasive external pacing.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
at least 8 years of age (for AED Therapy), adults (for SMART Biphasic waveform clinical testing)
Intended User / Care Setting
qualified medical personnel, trained in either Advanced Cardiac Life Support or in the operation of the device, in a hospital environment.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Waveform analysis, comparing the performance of the Heartstream XL BTE . waveform to the LifePak 12 BTE waveform at various energy and impedance levels typical of intra-thoracic applications.
. Animal test data, comparing the performance of the Heartstream XL BTE to the Likepak 12 BTE in domestic swine.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
LIFEPAK 12 Defibrillator/Monitor, Heartstream XL Defibrillator/Monitor
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.5310 Automated external defibrillator system.
(a)
Identification. An automated external defibrillator (AED) system consists of an AED and those accessories necessary for the AED to detect and interpret an electrocardiogram and deliver an electrical shock (e.g., battery, pad electrode, adapter, and hardware key for pediatric use). An AED system analyzes the patient's electrocardiogram, interprets the cardiac rhythm, and automatically delivers an electrical shock (fully automated AED), or advises the user to deliver the shock (semi-automated or shock advisory AED) to treat ventricular fibrillation or pulseless ventricular tachycardia.(b)
Classification. Class III (premarket approval)(c)
Date PMA or notice of completion of PDP is required. A PMA will be required to be submitted to the Food and Drug Administration by April 29, 2015, for any AED that was in commercial distribution before May 28, 1976, or that has, by April 29, 2015, been found to be substantially equivalent to any AED that was in commercial distribution before May 28, 1976. A PMA will be required to be submitted to the Food and Drug Administration by April 29, 2015, for any AED accessory described in paragraph (a) that was in commercial distribution before May 28, 1976, or that has, by April 29, 2015, been found to be substantially equivalent to any AED accessory described in paragraph (a) that was in commercial distribution before May 28, 1976. Any other AED and AED accessory described in paragraph (a), shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.
0
510(k) Summary for Heartstream XL. Defibrillator/Monitor
K021 453
Date Summary Prepared
May 3, 2002
r "
Submitter's Name and Address
Philips Medical Systems Healthcare Solutions Group 3000 Minuteman Road Andover, MA 01810-1099
Contact Person
Richard J. Petersen Philips Medical Systems Cardiac Resuscitation Solutions Division Telephone: (978) 659-2213 Facsimile: (978) 659-7360
Device Name
| Proprietary Name: | Heartstream XL Defibrillator/Monitor |
|---|---|
| Common Name: | Defibrillator/Monitor |
| Classification Names: | Low-Energy Defibrillator |
Predicate Devices
The legally marketed devices to which Philips Medical Systems claims equivalence for the Heartstream XL Defibrillator/Monitor are as follows:
- LIFEPAK 12 Defibrillator/Monitor, Medtronic Physio-Control Corp. .
- Heartstream XL Defibrillator/Monitor, Philips Medical Systems .
The design of the proposed Heartstream XL Defibrillator/Monitor is substantially equivalent in safety and performance to the devices listed above.
Device Description
The Heartstream XL Defibrillator/Monitor is a full-featured manual defibrillator, designed for use by clinicians trained in Advanced Cardiac Life Support (ACLS) procedures. Manual operation allows users to select biphasic waveform energy levels for external defibrillation, intra-thoracic defibrillation, delivery of synchronized shocks, and noninvasive external pacing.
1
Intended Use
, l
The Heartstream XL Defibrillator/Monitor is a fully featured, defibrillator intended for use by qualified medical personnel, trained in either Advanced Cardiac Life Support or in the operation of the device, in a hospital environment.
Comparison of Technology Characteristics
The Heartstream XL's Biphasic Truncated Exponential waveform utilized for intrathoracic defibrillation shocks, is similar to the BTE waveform used in the LIFEPAK 12.
Nonclinical Tests Used in Determination of Substantial Equivalence
The testing performed to show substantial equivalence to the Lifepak 12 included:
- Waveform analysis, comparing the performance of the Heartstream XL BTE . waveform to the LifePak 12 BTE waveform at various energy and impedance levels typical of intra-thoracic applications.
- . Animal test data, comparing the performance of the Heartstream XL BTE to the Likepak 12 BTE in domestic swine.
Conclusion from Testing
Based on the results of the testing described above, it is concluded that the Heartstream XL BTE waveform for intra-thoracic defibrillation applications does not raise any different questions regarding the safety or effectiveness as compared with the predicate devices. It is considered to be substantially equivalent to the predicate devices.
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is an abstract symbol resembling three human profiles facing right, arranged in a stacked, flowing manner.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
3 2002 . JUL
Philips Medical Systems c/o Mr. Richard J. Peterson 3000 Minuteman Road Andover, MA 01810
Re: K021453
Heartstream XL M4735A Defibrillator/Monitor Regulation Number: 870.1025, 870.5300 Regulation Name: Automated External Defibrillator, DC-Defibrillator Low Energy (Including Paddles) Regulatory Class: III (three)
Product Code: MKJ, LDD Dated: May 3, 2002 Received: May 6, 2002
Dear Mr. Petersen:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
3
Page 2 - Mr. Richard J. Peterson
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of vour device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
Duta Tell
Donna-Bea Tillman, Ph.D. Acting Director Division of Cardiovascular and Respiratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Indications for Use
510(k) Number (if known): To be assigned
Device Name: Philips Medical Systems, Heartstream XL Defibrillator/Monitor
Indications For Use: The Heartstream XL Defibrillator/Monitor is for use for the termination of ventricular tachycardia and ventricular fibrillation.
The device is for use by qualified medical personnel trained in the operation of the device and qualified by training in basic life support, advanced cardiac support, or defibrillation. It must be used by or on the order of a physician.
The SMART Biphasic waveform utilized in the Heartstream XL Defibrillator/Monitor has previously undergone clinical testing in adults. These trials support the waveform's effectiveness for defibrillation of ventricular tachyarrhythmias at 150J.
AED Therapy: To be used in the presence of a suspected cardiac arrest on patients of at least 8 years of age that are unresponsive, not breathing and pulseless.
Manual Defibrillation: Asynchronous defibrillation is the initial treatment for ventricular fibrillation and ventricular tachycardia in patients that are pulseless and unresponsive. The SMART Biphasic waveform utilized in the Heartstream XL Defibrillator/Monitor incorporates some user selectable lower energy levels that were not used in the clinical trials.
Synchronized defibrillation is indicated for termination of atrial fibrillation. The SMART Biphasic waveform utilized in the Heartstream XL has undergone clinical testing demonstrating its safety and effectiveness for cardioversion of atrial fibrillation.
There are currently no clinical studies related to the use of SMART Biphasic waveform in pediatric applications.
Pacing: Noninvasive pacing is one method of treating patients with symptomatic bradycardia. It can also be helpful in patients with asystole, if performed early.
SpO2 Monitoring: SpO2 monitoring is indicated for use when it is beneficial to assess a patient's oxygen saturation level.
| (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE) | |
|---|---|
| Concurrence of CDRH, Office of Device Evaluation (ODE Off) | Division of Cardiovascular and Respiratory Devices |
| 510(k) Number | K021453 |
| Prescription Use | ✓ |
| or Over-The-Counter Use | |
| (Per 21 CFR 801.109) |